Journal
JOURNAL OF VIROLOGY
Volume 77, Issue 21, Pages 11367-11377Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.77.21.11367-11377.2003
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA086881, 1R41CA 91608-01, P50 CA89019, R01 CA86881, P50 CA089019] Funding Source: Medline
Ask authors/readers for more resources
The success of gene therapy depends on the specificity of transgene delivery by therapeutic vectors. The present study describes the use of an adenovirus (Ad) fiber replacement strategy for genetic targeting of the virus to human CD40, which is expressed by a variety of diseased tissues. The tropism of the virus was modified by the incorporation into its capsid of a protein chimera comprising structural domains of three different proteins: the Ad serotype 5 fiber, phage T4 fibritin, and the human CD40 ligand (CD40L). The tumor necrosis factor-like domain of CD40L retains its functional tertiary structure upon incorporation into this chimera and allows the virus to use CD40 as a surrogate receptor for cell entry. The ability of the modified Ad vector to infect CD40-positive dendritic cells and tumor cells with a high efficiency makes this virus a prototype of choice for the derivation of therapeutic vectors for the genetic immunization and targeted destruction of tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available